Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am working on a new APP.. I call it FUDAWAY. It is better than just "IGNORE". Some features include; automatic screening for 5 year old level thinking by poster, recurring theme sensor b/c I don't get paid to be smart, automatic "C'MON MORON " reply w/o typing and using precision Ihub posts. More to follow.
Suggestions for new features??
TAU , HUH....hope there is some science that shows causal relation.
Jon...very well done. You have linked facts w/the point made earlier by Investor 2014. He emphasized the importance as your article states.
Nicely done and an important link to keep in mind. Dr.M. is a bright guy, he chose the Poster title wording very carefully. It fits exactly w/the science as pointed out so well here and it ties word for word with what Anavex has been saying for a long time. Word for word. Nice indeed.
This is not a fantasy, it is really going to happen. Precision Medicine will require scientific facts, hopefully well understood. We all understand that it is the god given right of every scientist to start from scratch and to argue w/divergent theories. BUT, the AD Amyloid BP/WS crowd deliberately ignored powerful contradictory facts about Amyloid Tau for years while patients suffered and died. That, IMO cannot be considered good science, well practiced.
It will be interesting to see how many Posters @AAIC 2018 will include Amyloid in the title.
Exactly, CNS diseases have left deep scars in many families and our great scientific studies have only nibbled around the edges. Do not want to go down the rat hole on why at this point.
Getting older is no fun, IMO. That moment when you realize hey, what just happened is bad enough. Then, to have to face years of diminishing body functional capability on even the most basic stuff really sucks.
I am not qualified to fully understand what "restoration and regeneration" translates to in terms of projecting adult capabilities but ..."Bring it on ", it has to be better than the alternative. And, how about these dear little kids w/RS and all the rest of CNS indications. The stakes could not be higher. If not now then certainly soon.
BTW, it will be interesting to watch how WS parasites react when they see the scenario that is shaping up. All the corrupt games will have to be adapted to the new rules of Precision Medicine for Bio products development. They are a clever bunch so they will do something but now they better understand sp are based on science. The trials will not be on IF it Works BUT only on HOW WELL and what is that worth?
https://ep70.eventpilot.us/web/planner.php?id=AAIC18LITE#view1
If anyone is able to get and deliver here all the related information it would be great addition.
The second topic is also important as it the regeneration/restoration message is almost miraculous by inference.
Agree w/all said, particularly the sense about corruption.
Also note; the new FDA precision science protocols/workflow models are certain to throw a curve to those who are stuck on the old FDA-BP- biotech models. No more massive trials w/o a clue as to what the outcome will be. Trials will be smaller/shorter and CNS knowledge based. The new methods will emphasize planning and acceptance criteria with a target of simply verifying what clinical results have already demonstrated using AI models of known accuracy. Hopefully this will limit the entire placebo-trial size- back and forth we have suffered with for decades.
A classic BIIB "evergreen" project.
Biostock, thanks for your kind words your thoughts are highly valued, many thanks.
Maybe you have a suggestion on something I have been pondering. Can we do a retrospective application of the Australian safety trial results on A2-73 using RWE rules. The painter, golfer, piano player (others) ? If we applied the RWE rules and then learn we must exclude their (evidence) use then that is value added also. However if the "Anecdotes" are reviewed and converted to usable scientific process records then that changes things. AVXL has to get the process for doing this figured out anyways. Why not do a retrospective application using the patients from Australia?
BTW, we can get out in front of the FUD guys who are certain to call future RWE worthless anecdotes.
I have great respect for the reasoning skills of many on the board. However, we need to establish a different context for CNS trails being developed and implemented under precision medicine guidance. The point has been made here about FDA previous trials when done by BP. They were for the most part stand alone, shot gun processes with very little evidence of scientific root cause analysis at their core. In fact, for example, there was a lot of evidence that contradicted the AD amyloid-Tau causal relation but practices chose to ignore the contradictions and of course they repeatedly failed. The science was weak and could not be validated, unlike what has been done in Oncology.
Dr.M. has clearly stated in recent discussions again that AVXL is different and he is correct. In a way we are fortunate that no trial has yet provided evidence of causal analysis for any CNS diseases, sadly they remain untreatable. But, precision medicine is different. The very first evidence we have of efficacy(see RWE) in treating any of the various indications using a repeatable-fact based scientific process will make the entire time based, ridiculously expensive, methods of the past irrelevant. We are now in a learning process which will ultimately allow the cause of each indication to be understood, even if it requires one patient at a time resolution. The big challenge is in selecting and assessing the markers and verifying that the process is transferable and repeatable to all patients. No more shotguns. IMO we are basically looking at a form of outpatient treatments for CNS diseases in the near future.
We cannot apply the weapons and tactics of the last war to the one we are in now, we will lose if we do. IMO, SP will be extremely volatile when this new concept is fully understood and applied by investors. If we have the science get on and stand by, if not get off b/c you are not going anywhere. I think we got this.
ASCO...
Wolf...very strong message. Appreciate it.
Wouldn't it be great to get some good news for once.
Huh, thanks ...what you suggest makes sense in this instance.
Kentucky...it was explosive and nice to see. Looking fwd to a lot more of it.
9:00 AM–10:15 AM
Jun 7, 2018
Brain Health
Exposing Cracks in the Armor of Brain Diseases
Speakers
Mr. John Alam, ACHACEO atEIP Pharma
Dr. Jeff Gulcher, MD,PhDCSO atWuXi NextCODE
Christopher MisslingPresident & CEO atAnavex Life Sciences
Aidan Power, BCH,MB,MRCP,MScVice President of Program and Portfolio Management atAlzheon
Dr. George VlasukCEO atNavitor Pharmaceuticals
Location
Room 255, Level 2
9:00 AM–9:45 AM
Jun 7, 2018
Fireside Chat with Dr. Scott Gottlieb, Commissioner, US Food and Drug Administration
Speakers
Scott Gottlieb, MDCommissioner of Food and Drugs atUS Food and Drug Administration
James GreenwoodPresident and Chief Executive Officer atBiotechnology Innovation Organization
Thanks, looks like we are in for a rough patch unless we get ++ news.
Hi Xena, the first 10 mins or so shows 2x the normal daily volume and of course yesterday was off the charts. You usually have this kind of thing figured out. I am hiding and watching this hoping we not now obligated to do the daily tree shaking exercise again. What is going on in your opinion?
I think there is some reason but the cloak of silence is down.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm609647.htm
This may be a factor in why we are up so nicely today.
Posted earlier by another poster here. This reads a lot like an FDA Mea Culpa about their processes and related reversals. Dr. Gottlieb may feel obligated (June 4, 2018) due to serious and obvious FDA process management issues which we have discussed here (BP/Amyloid-BC/Chemo.
It's all about process and details. Some stealth PR's are follow up to process changes such as this. Obviously FDA have not completely thought this out based on a quick read. IMO, this FDA release has consequences, we just do not know what they are yet. But, good news is all in AVXL process wheelhouse while BP is just so screwed. Got to be a factor. Just consider how much of a turnaround in the AD space has occurred in the past 3-6 months.
Many thanks to the other poster for finding and posting it.
Looking..Great catch here:
Hey John....I am w/you on the direction, would prefer teens (x20+) ...all the best.